In part 6 of this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the positive factors of V-Go and the patients who can use it.
Scott Abbott is the Director of Medical Development at Valeritas.
Transcript of this video segment:
Steve: When was this FDA approved and when did it come to market?
Scott Abbott: It became available in 2012, so we have been steadily bringing this out across the United States since that time.
Steve: So it’s been available for 5 years.
Scott Abbott: That’s right, we have publicly disclosed over 10 million days of therapy, so 10 million devices.
Steve: Is this approved for both type 1 and type 2?
Scott Abbott: It’s approved for adults who require insulin. So yes, type 1 and type 2 would apply. It’s mostly used in patients with type 2 diabetes. That’s who it was originally designed for mostly because of the insulin dosing I described earlier.
Steve: Are there any other factors that you have shown to be positive? There’s the convenience and a lot of other things.
Scott Abbott: There’s the insulin does…the economics are there. We do our analyses and most of our studies are done as real-world or pragmatic designs so that it can be applicable to the general population. And that’s important, because you want to know that a therapy can be used by a lot of different types of patients and patients that clinicians treat. What we do normally in our economic analyses is we use the acquisition cost of therapy price and we take a look at the cost of therapy for their diabetes management and patients who are on V-Go and not on V-Go. You see what the cost-factors are in terms of how much does it cost to treat diabetes to get a certain result, and we have seen the cost benefit for that.